Saptalis Pharms Company Profile

What is the competitive landscape for SAPTALIS PHARMS, and when can generic versions of SAPTALIS PHARMS drugs launch?

SAPTALIS PHARMS has twenty-two approved drugs.

There is one US patent protecting SAPTALIS PHARMS drugs.

There are five patent family members on SAPTALIS PHARMS drugs in five countries and seventy-nine supplementary protection certificates in fifteen countries.

Summary for Saptalis Pharms

International Patents:	5
US Patents:	1
Tradenames:	20
Ingredients:	20
NDAs:	22

Drugs and US Patents for Saptalis Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Saptalis Pharms	VOSOL HC	acetic acid, glacial; hydrocortisone	SOLUTION/DROPS;OTIC	012770-001	Approved Prior to Jan 1, 1982	AT	RX	Yes	Yes
Saptalis Pharms	NEMBUTAL	pentobarbital sodium	SUPPOSITORY;RECTAL	083247-002	Jan 25, 1982		DISCN	No	No
Saptalis Pharms	NEMBUTAL	pentobarbital sodium	SUPPOSITORY;RECTAL	083247-003	Jan 25, 1982		DISCN	No	No
Saptalis Pharms	LITHIUM CITRATE	lithium citrate	SYRUP;ORAL	217183-001	Mar 18, 2024	AA	RX	No	No
Saptalis Pharms	NEMBUTAL	pentobarbital sodium	SUPPOSITORY;RECTAL	083247-004	Jan 25, 1982		DISCN	No	No
Saptalis Pharms	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	SPRAY;TOPICAL	207094-001	Dec 7, 2016	AT	RX	No	No
Saptalis Pharms	LOPERAMIDE HYDROCHLORIDE	loperamide hydrochloride	SOLUTION;ORAL	074352-001	Nov 17, 1995		DISCN	No	No

International Patents for Saptalis Pharms Drugs

Country	Patent Number	Estimated Expiration
Mexico	2020007494
Brazil	112020014376
European Patent Office	3768321
World Intellectual Property Organization (WIPO)	2019140516
Canada	3087789

Supplementary Protection Certificates for Saptalis Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	300677	Netherlands		PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2498758	CA 2020 00017	Denmark		PRODUCT NAME: METFORMIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; SAXAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SOLVAT DERAF; REG. NO/DATE: EU/1/19/1401 20191113
1412357	C300357	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
1506211	122014000070	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116
1506211	CA 2014 00037	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
1506211	SPC/GB14/050	United Kingdom		PRODUCT NAME: A COMBINATION OF DAPAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METFORMIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/900 20140121
2498758	16/2020	Austria		PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 (MITTEILUNG) 20191113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Saptalis Pharms